DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20205320

Correlation of cyclin D1 between hormones receptors and other clinical parameters in invasive breast carcinoma

Seema Singh, Abdul Mabood, Neetu Dwivedi, M. Qamar Alam, Abhinav Gangwar

Abstract


Background: Breast carcinoma is the most common malignancy in women. The prognosis of breast carcinoma is determined by different prognostic factors including age of patients, type of tumour, stage of tumours, grade of tumors, presence or absence of metastasis and hormones receptor status. The present study was conducted to assess the expression of cyclin D1 in invasive breast carcinoma and its correlation with age, tumour grade, lymph node metastasis and hormones receptors (estrogen receptors and progesterone receptors).

Methods: Present study was conducted in department of pathology UPUMS, Saifai, Etawah, Uttar Pradesh. This was a prospective cross sectional observation study conducted on 21 mastectomy specimen from January 2019 to June 2020, diagnosed as invasive breast carcinoma on routine haematoxylin and eosin stain. Immunohistochemistery marker was scored by using allred scoring methods. Grading was calculated according to Nottingham grading system.

Results: It was observed out of 21 cases 9 (42.8%) cases were showing cyclin D1 positivity. In our study 14 cases were estrogen receptor and progesterone receptor positive, out of 14 ER and PR positive cases 9 (64.2%) cases showing cyclin D1 positivity. There was significant correlation between cyclin D1 and hormones receptors (ER and PR). No significant correlation between cyclin D1and age, tumour grade and lymph node metastasis.

Conclusions: Present study depicts significant correlation between cyclin D1 and hormones receptors (ER and PR). No significant correlation between cyclin D1and age, tumour grade and lymph node metastasis.


Keywords


Invasive breast carcinoma, Cyclin D1, ER, PR

Full Text:

PDF

References


Thorat MA, Badve S. Prognostic factors in invasive breast carcinoma: Do new molecular techniques/ profiling add significantly to traditional histological factor?. Curr Diagn Pathol. 2007;13:116-25.

Lundberg A, Lindstrom LS, Li J. The long –term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumour. Breast Cancer Res. 2019;21:34.

Inoue K, Elizabeth A. Aberrant expression of cyclin D1 in cancer. Sign Transduct Insights. 2015;4:1-13.

Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11:155-6.

Wolff AC, Hammonad ME, Schwartz JN. American society of clinical oncology /College of American Pathologist Clinical guidelines recommandations for human epidermal growth factor receptor2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.

Joe AK, Memeo L, Mckoy J, Manusukhani M, Liu H, Avila BA . Cyclin D1 over expression is associated with estrogen receptor expression in Caucasian but not in Afrian American breast cancer. Anti Cancer Res. 2005;25:273-81.

Sicinski P, Weinberg RA. A specific role for cyclin D1 in mammary gland development. J Mammary Gland Bio Neoplasia. 1997;2:335-42.

Saidati S, Sharbatdara M, Nikbakhsh N, Ghaemia N. Correlation of ER, PR and HER-2/Neu with other prognostic factors in Infiltrating factors ductal carcinoma of breast. Iran J Pathol. 2015;10(3):221-6.

Lengare A. Immnohistochemical expression of cyclin D1 in invasive breast carcinoma and its correlation with clinicopathological parameters. Indian J Pathol Microbiol. 2020;63(3):376-81.

Sarkar S, Kanoi A, Bain J, Gayen R, Das K. Correlation between cyclin D1 expression and standard clinicopathological variables in invasive breast cancer in Eastern India. South Asian J Cancer. 2015;4(4):155-9.

Anders C, Johnson R, Litton J, Phillips M, Bleyer A . Breast cancer before age 40 years. Semin Oncol. 2009;36(3):237-49.

Madani SH, Payandesh M, Sadeghi M, Montamed H, Sadeghi E. The correlation between Ki-67 with other prognostic factors in breast cancer : A study in Iranian patients . Indian J Med Peadiatr Oncol. 2016; 37(2):95-8.

Mohammadizadeh F, Hani M, Ranaee M, Bagheri M. Role of cyclin D1 in breast carcinoma. J Res Med Sci. 2013;18(12):1021-5.

Hearne B, Teare MD, Butt M, Donaldson. Comparison of Nottingham prognostic index and adjuvant online prognostic tools in young women with breast cancer: review of a single –institution experience. BMJ Open. 2015;5:5576.

Mohapatra M, Satyanarayana S. Evaluation of clinic: Pathological findings of breast carcinoma in a general hospital in Southern India. Indian J Cancer. 2013;50:297-301.

Fong Y. The Nottingham prognostic Index: five and ten year data for all cause survival within a screened population. Ann R Coll Surg Engl. 2015;97(2):137-9.

Ravi KG, Ananthamurty A. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters. J Cancer Res Ther. 2014;10(3):671-5.